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A comparison between transposed brachiobasilic
arteriovenous fistulas and prosthetic brachioaxillary
access grafts for vascular access for hemodialysis
Andy Robert Weale, MRCS, Paul Bevis, MRCS, William D. Neary, MRCS, Paul A. Lear, MS, FRCS,
and David C. Mitchell, MS, FRCS, Bristol, United Kingdom
Objective: Patients requiring access for hemodialysis in whom radiocephalic or brachiocephalic arteriovenous fistulas
cannot be formed or have failed present a significant clinical challenge. We compare outcomes in patients undergoing
transposed brachiobasilic arteriovenous fistulas (BBAVF) with expanded polytetrafluoroethylene brachioaxillary access
grafts in a single European center.
Methods: We identified all patients undergoing a first upper limb tertiary-access procedure—that is, either BBAVF or
brachioaxillary access graft for hemodialysis—between January 1, 2000, and December 31, 2005. The median follow-up
was 18.1 months (interquartile range, 8.7-34.9 months). Successful use for dialysis, primary patency, secondary patency,
and patient survival was assessed.
Results: A total of 185 patients were identified; 71 had a BBAVF, and 114 had an access graft. The median age was 64.3
years (interquartile range, 50.7-74.4 years). The groups were well matched for age, sex, ethnicity, diabetes, and number
of prior access procedures. Significantly fewer BBAVFs were successfully used for dialysis: 69.0% BBAVFs compared with
89.4% access grafts (P  .001; 2). One- and two-year primary patency rates were 45.3% and 40.0%, respectively, for
BBAVF and were 56.4% and 43.2% for access grafts (P .579; log rank). Furthermore, there was no significant difference
in secondary patency between the two procedures (P  .868; log rank). We found that surgeons in training had no
influence on the primary patency of either BBAVF or access grafts. However, infective complications necessitating an
operation were significantly higher in the access graft group (6.2% vs 0%; P  .031; Fisher exact test).
Conclusions: Although more difficult to establish, BBAVFs provide patency at least equivalent to that of brachioaxillary
access grafts. However, infective complications are fewer in the BBAVF group. As such, we believe that BBAVF should
be the first choice of the vascular access surgeon when fistulas using the cephalic vein are not possible or have failed.
(J Vasc Surg 2007;46:997-1004.)Patients who are unable to undergo dialysis by using a
radiocephalic or brachiocephalic arteriovenous fistula
(AVF), because of either unsuitable anatomy or access
failure, present a common challenge.1,2 If suitable, the
basilic vein may be anastomosed to the brachial artery. To
form an easy-to-needle autogenous brachiobasilic AVF
(BBAVF), the vein may be elevated or transposed either at
the time of fistula formation (stage 1) or after arterialization
of the vein some weeks after the initial fistula formation
(stage 2).3,4 Primary failure rates vary widely in the litera-
ture, with between 0%5,6 and 38%7 of fistulas not maturing
to use. Primary patency rates range from 23%8 to 90%5,9 at
1 year, with secondary patency rates of 47% to 96%.5,7
Although minimally invasive techniques have been de-
scribed,10 most patients require a long medial arm incision
to isolate the basilic vein. Given this extensive dissection
and the disappointing patency of BBAVF in some series,
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doi:10.1016/j.jvs.2007.07.023there remains enthusiasm for the readily useable prosthetic
access graft inserted in the forearm loop11 or the straight
brachioaxillary configuration.12
Comparisons between isolated series of prosthetic ac-
cess grafts and BBAVF inevitably suffer from center effects.
To date, only four studies have compared BBAVF with
upper limb prosthetic access grafts9,13-15 (Table I). Al-
though the first two studies showed clear advantages in
terms of patency over prosthetic grafts,9,13 the more recent
studies have found little difference in patency when ana-
lyzed on an intention-to-treat basis.14,15 Oliver et al14 had
to exclude the 21% of BBAVFs that failed primarily before
a statistical difference in patency could be demonstrated
over prosthetic grafts. Nevertheless, all studies have clearly
demonstrated that autogenous BBAVFs have lower infec-
tion rates than prosthetic grafts.
Of the four studies, three were from North American
centers, and one was from Taiwan. Thus, no study has been
published from a European center comparing the out-
comes of BBAVF with upper limb prosthetic grafts. Given
the different patterns of access between Europe and North
America,16,17 we hypothesized that differences between
the two procedures may be exaggerated in centers with
higher overall autogenous access placement. As such, we
embarked on this retrospective comparison of patency and
complication rates between BBAVF and prosthetic bra-
chioaxillary grafts in a single European center.
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Patients. We identified every patient undergoing his
or her first surgical procedure for vascular access in our
center between January 1, 2000, and December 31, 2005.
Within this cohort we studied all patients who went on to
require an access procedure in the upper arm (tertiary
access; that is, BBAVF or a straight brachioaxillary pros-
thetic access graft). Thus, any patient who had undergone
any surgical access procedure before January 1, 2000 was
excluded from the analysis. Only the first tertiary access
procedure in the arm was considered in the analysis. It
should be noted that because of surgical preference, only a
few (n 4) forearm loop grafts11 were inserted during the
time period; because this group is not large enough to
perform a meaningful analysis, these patients were not
considered.
Cases were identified by using the hospital’s comput-
erized renal patient records and cross-checked with operat-
ing room records. Patients’ age, sex, ethnic group, diabetic
status, access history, and date first seen by a nephrologist
were recorded. The main surgeon was identified by using
the operative record.
Operations. Before surgery all patients were assessed
clinically by one of two experienced consultant vascular
access surgeons (P.A.L. and D.C.M.). During the study,
preoperative duplex scanning or venography was per-
formed selectively. We identified all patients who had a
preoperative duplex scan and recorded the minimum diam-
eter of the basilic vein identified.
All operations were performed with patients under
general anesthesia. All BBAVFs were formed as described
by Dagher et al,3 and most were a one-stage procedure.
Briefly, a single long incision or incision with a skin bridge
was made in the medial aspect of the arm and deepened to
expose the basilic vein from antecubital fossa to axilla.
Tributaries were ligated, and the vein was isolated. Once
free, it was disconnected in the antecubital fossa. The vein
was then tunneled subcutaneously and anastomosed end to
side to the brachial artery with 6-0 Prolene (Ethicon, Inc,
Somerville, NJ), in or just proximal to the antecubital fossa.
No completion angiography was performed. Brachioaxil-
lary access grafts required exposure of the axillary vein and
brachial artery via small incisions in the axilla and antecubi-
Table I. Studies comparing BBAVF and vascular access gr
Type
Coburn 19949
Rhode Island, USA
BBAVF
PTFE
5
4
Matsuura 199813
Georgia, USA
BBAVF
PTFE
3
6
Oliver 200114
North Carolina, USA
BBAVF
PTFE
5
8
Lee 200415
Taipei, Taiwan
BBAVF
PTFE
2
5
PTFE, Polytetrafluoroethylene, BBAVF, brachiobasilic arteriovenous fistulatal fossa, respectively. Six-millimeter expanded polytetra-fluoroethylene was tunneled subcutaneously in a straight
configuration, and the graft was anastomosed to the vein
and artery end to side by using 6-0 Prolene. Routine
postoperative anticoagulation was not used. Postoperative
duplex investigation and surveillance were performed only
in patients in whom fistulas or grafts failed to mature or in
whom dialysis was poor.
Outcome. Renal patient records were accessed in Oc-
tober 2006 to identify the outcome of each fistula. Median
follow up was 18.1 months (interquartile range [IQR],
8.7-34.9 months). A successful fistula/graft was defined as
a fistula or graft that had been successfully needled for
dialysis. The presence or absence of a thrill was not used to
define technical success, because the simple presence of a
thrill does not determine whether a fistula will mature to
become usable or can be used for dialysis.18 Primary func-
tional patency was defined according to the recommended
reporting standards25—ie, the percentage of all BBAVFs/
grafts attempted that were still being used for dialysis that
had not required any intervention designed to maintain or
re-establish patency at 1 and 2 years.19 Interventions in-
cluded angioplasty, thrombectomy, and surgical revision of
the fistula. Secondary functional patency was defined as the
percentage of all BBAVF/grafts attempted that were being
used irrespective of interventions to re-establish or main-
tain patency at 1 and 2 years. The time to first use and the
dates of death or transplantation were recorded as relevant.
Patients who underwent transplantation, died, or never
proceeded to long-term hemodialysis were considered as
lost to follow-up and were censored for all survival analysis.
Differences in patient survival were also investigated.
Infections necessitating operative intervention (inci-
sion and drainage of collection related to graft or BBAVF)
or loss or excision of access were identified. Operations
performed for steal syndrome were also noted (access liga-
tion or distal revascularization and interval ligation20 pro-
cedure).
Statistical analysis. Patient demographic factors were
compared by using the Mann-Whitney U test for continu-
ous variables and 2 tests for categorical values. For fistula
success, proportions were compared by using a 2 test.
Fistula patency, fistula survival, and patient survival
were analyzed by using life tables and Kaplan-Meier survival
1 year patency 2 year patency
90% (primary)
70% (primary)
86% (primary)
49% (primary)
70% (primary)
46% (primary)
64% (cumulative)
62% (cumulative)
70% (cumulative)
69% (cumulative)afts
N
9
7
0
8
9
0
0
0analysis. The two groups were compared by using a log-
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attempts, prior functioning AVF, and grade of surgeon)
potentially influencing the primary patency of BBAVF and
access grafts were analyzed with a Cox proportional hazards
regression analysis. In patients who had a preoperative
duplex scan, we assessed the effect of minimum basilic vein
diameter on BBAVF primary patency.
Statistical analysis was performed with SPSS (version
12.0 for Windows; SPSS Inc, Chicago, Ill). A P value of
.05 was considered statistically significant
RESULTS
During the study period, 716 patients underwent 1007
procedures to create vascular access for hemodialysis. A
total of 361 patients had a radiocephalic fistula formed, and
297 had a brachiocephalic fistula formed as the first access
procedure. Twenty (2.8%) had a BBAVF, and 38 (5.3%)
had a vascular access graft as the primary procedure. Patient
demographics are shown in Table II.
Of the 658 patients who had a radiocephalic or bra-
chiocephalic fistula as the primary surgical access procedure
during the study period, 126 patients required either a
BBAVF (n 51) or a brachioaxillary access graft (n 76).
Thus we were able to compare 71 BBAVF with 114 bra-
chioaxillary access grafts.
It is worthy of note that during the study, 253 patients
underwent 319 tertiary access procedures (103 BBAVFs
and 216 access grafts). Sixty-eight patients who had under-
gone a surgical access procedure before 2000 where ex-
cluded. Thirty-four of the 253 had more than one tertiary
access procedure; only the first access procedure was con-
sidered. Thus, although the comparison is not a consecu-
tive series of all access grafts and BBAVFs, it considers only
the first tertiary access procedure and does not suffer from
double inclusion of patients.
Significantly fewer BBAVFs were ever used for dialysis
than access grafts; 49 (69.0%) BBAVFs compared with 102
(89.4%) access grafts (P  .001; 2). Of the 22 patients
with a BBAVF that was never used for dialysis, 4 did not
Table II. Patient demographics
Access graft (n
Age 66.3 (52.9-7
Females 64 (56.1%
Diabetes 50 (43.9%
Ethnic group:
Caucasian 101 (88.6%
Black 2 (1.7%)
Asian 10 (8.8%)
Chinese 1 (0.9%)
Previous operations (median (IQR)) 1 (0-2)
Previous successful dialysis using either
a radio-cephalic or brachiocephalic
fisutla 34 (29.8%
First seen by nephrologist 3 months
prior commencing hemodialysis 33 (28.9%
BBAVF, Brachiobasilic arteriovenous fistula; IQR, interquartile range.actually ever proceed to dialysis. Although a good bruit wasdocumented in all of these patients, we have not classified
these patients as having a successful fistula, because it is well
recognized that the presence of a thrill does not determine
whether a fistula can be used for dialysis.18 Thrombosis
occurred in 18 (25.3%) BBAVFs before dialysis: 6 patients
had a BBAVF that failed within 30 days of the procedure,
whereas of the 12 BBAVFs that thrombosed later without
being successfully used for dialysis, only 2 patients pre-
sented to the hospital for an attempted thromboembolec-
tomy. One of these had a procedure that successfully re-
stored blood flow. Of the 12 patients who had an access
graft that was never needled, only 1 did not actually pro-
ceed to dialysis. Two patients required removal of the graft
within the first week as a result of steal, whereas a further
five patients had graft thrombosis within 30 days. Three of
these patients attended the hospital and underwent success-
ful thromboembolectomy. However, reclotting of these
grafts occurred within weeks, and further access creation
was required in all cases. Of the four patients with failure
after 30 days and nonuse, three had graft revisions before
thrombosis and loss of access.
The median time to first use for BBAVF was 71 days
(IQR, 45-107 days). The median time to first use for access
grafts was significantly shorter (P  .001; Mann-Whitney
U test), at 14 days (IQR, 13-14 days).
The primary functional patency of BBAVFwas 45.3% at
1 year and 40.0% at 2 years. The 1- and 2-year primary
patency rates of access grafts were 56.4% and 43.2%, respec-
tively. There was no difference in primary functional pa-
tency between BBAVF and access grafts (P  .579; log-
rank test), as illustrated in the survival curve in Fig 1. The
secondary functional patency of BBAVF was 53.6% at 1
year and 50.9% at 2 years. Fifteen patients with a BBAVF
underwent surgical revision (n  4), thromboembolec-
tomy (n  4), angioplasty (n  6), or both surgical and
radiologic intervention (n  1) to maintain patency of the
fistula. One- and two-year secondary patency rates of access
grafts were 61.7% and 41.1%, respectively. Twenty-four
patients with an access graft underwent surgical revision (n
) BBAVF (n  71) P value
61.5 (48.6-73.0) 0.225 (Mann-Whitney)
38 (53.5%) 0.728 (2)
33 (46.5%) 0.727 (2)
0.787 (2)
66 (93.0%)
1 (1.4%)
4 (5.6%)
0
1 (0-1) 0.904 (2)
16 (22.5%) 0.262 (2)
13 (18.3%) 0.104 (2) 114
4.5)
)
)
)
)
) 5), thromboembolectomy (n 15), angioplasty (n 1),
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tency. There was no significant difference between the need
for interventions (P  .990; 2), the number of interven-
tions (P  .962; Mann-Whitney), or overall secondary
functional patency (Fig 2; P .868; log-rank test) between
the two procedures. Even when primary failures were ex-
cluded and only the patency of access that had gone on to
function (needled for dialysis) was considered, there re-
mained no difference between the two access procedures in
terms of access survival (Fig 3).
We observed that age, female sex, late referral to ne-
phrology (dialysis within 3 months of first seeing a special-
ist), diabetes, number of previous access procedures, previ-
ous successful dialysis with a fistula, and grade of operator
(surgeon in training) had no effect on loss of primary
patency of either access grafts (Table III) or BBAVF (Table
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p=0.579
Access graft
BBAVF
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Fig 1. Primary patency of brachiobasilic arteriovenous fistula
(BBAVF) and polytetrafluoroethylene access grafts. The dashed
bar illustrates the point at which the Kaplan-Meier curve becomes
unreliable.
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BBAVF 71 48 24 16 12 6 6 5 2
Access graft 114 66 38 24 12 8 5 4 4 3 1
At risk
p=0.9553
Fig 2. Secondary patency of brachiobasilic arteriovenous fistula
(BBAVF) and polytetrafluoroethylene access grafts. The dashed
bar illustrates the point at which the Kaplan-Meier curve becomes
unreliable.IV).Just less than 60% (n  43) of the BBAVF group
underwent preoperative imaging of the upper limb with
duplex scanning before undergoing the procedure. Al-
though this incomplete subgroup should be interpreted
with caution, the median minimum measure size of the
basilic vein on duplex scanning in the 26 BBAVFs that were
successfully needled was 3.3 mm (IQR, 2.5-3.8 mm),
compared with 3.1 mm (IQR, 2.6-3.3 mm) in the 17 that
were never used (P .456; Mann-WhitneyU test). Eleven
BBAVFs were attempted in patients with a minimum mea-
sured vein diameter of 2.5 mm or less; in seven (63.6%) of
these patients, the fistula successfully matured to use. Of
the 32 patients who had a basilic vein measured at greater
than 2.5 mm, 19 (59.4%) veins were successfully used (P
.803; 2). Although the numbers are small and the results
should be interpreted cautiously, Fig 4 shows that there is
no difference in primary patency between BBAVF created
when vein diameters are smaller than or larger than 2.5 mm
(P  .9631; log rank).
Infective complications necessitating operative inter-
vention were more common (P  .031; Fisher exact test)
with access grafts (n  7 removed) than BBAVFs (n  0).
The incidence of steal syndrome was low in this series, with
no statistical difference in steal syndrome necessitating in-
tervention and with 2 grafts removed and no BBAVF
necessitating intervention (P  .378; Fisher exact test).
One BBAVF was tied off because it was implicated in the
patient’s cardiac failure; however, the patient’s symptoms
did not improve with fistula ligation.
Patients who had undergone a BBAVF had a better
survival rate than patients who only had an access graft
inserted (P  .001; log rank). This is shown in Fig 5.
DISCUSSION
This study is important in the context of changing
patterns of vascular access17 and in comparing outcomes
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Months following first use of access
BBAVF
Access graft
BBAVF 49 31 19 13 8 5 5 4 1
Access graft 101 60 36 22 10 8 5 4 4 2 1
At risk
p=0.2853
Fig 3. Access survival of brachiobasilic arteriovenous fistula
(BBAVF) and polytetrafluoroethylene access grafts. The dashed
bar illustrates the point at which the Kaplan-Meier curve becomes
unreliable.from upper arm prosthetic access grafts with transposed
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one of the largest series of BBAVFs in the literature to
date.21 We found that primary and secondary functional
patency is equivalent between the BBAVF and prosthetic
access grafts. This is in keeping with the two most recent
comparisons.14,15 The primary functional patency of
BBAVF at 1 year of 45.3% is at the lower end of that found
in the worldwide literature (Table V), but it is similar to
reports published within the last 5 years.7,8,15,22,23 It is
interesting to note that the patency rates of BBAVF are very
similar to the patency rates of radiocephalic and brachioce-
phalic fistulas we have previously published from our cen-
Table 3. Impact of factors on loss of primary patency of b
Exp(B
Age 0.989
Number of access procedures 1.112
Diabetes 0.839
Female sex 0.782
Dialysis within 3 months of referral 1.461
Previous dialysis with a fistula 0.704
Non-consultant operator 1.656
Table 4. Impact of factors on loss of primary patency of B
Exp(B
Age 0.997
Number of access procedures 0.792
Diabetes 1.498
Female sex 0.739
Dialysis within 3 months of referral 0.921
Previous dialysis with a fistula 0.707
Non-consultant operator 1.356
BBAVF, Brachiobasilic arteriovenous fistula.
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p=0.001
Fig 4. Patient survival of patients with a brachiobasilic arterio-
venous fistula (BBAVF) and polytetrafluoroethylene access grafts.
The dashed bar illustrates the point at which the Kaplan-Meier
curve becomes unreliable.ter.24 The patency rates were nonetheless disappointing,and we require changes to our access service in light of new
evidence.
Early failure rates in both grafts and BBAVF were also
higher than expected. This may relate to the low use of
preoperative imaging. We do not believe that the use of
general anesthesia has had a detrimental effect on early
outcome. Although it is recognized that both BBAVFs and
access grafts can be inserted by using regional blockade
and, indeed, that this may be preferable in terms of patient
risk and venodilatation,25 there is little evidence that re-
gional blockade improves patency in tertiary access. When
access procedures that did not result in a functioning graft
or fistula were excluded, we did not find that BBAVFs
provided greater longevity, although this may relate to the
io-axillary access grafts (Cox regression analysis)
95% CI P value
0.973-1.005 0.190
0.752-1.645 0.595
0.463-1.523 0.568
0.435-1.408 0.412
0.758-2.817 0.257
0.386-1.287 0.254
0.943-2.910 0.079
F (Cox regression analysis)
95% CI P value
0.975-1.020 0.787
0.525-1.194 0.265
0.777-2.891 0.228
0.384-1.423 0.366
0.375-2.259 0.857
0.296-1.688 0.436
0.661-2.784 0.406
Months following creation of access
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32 19 8 6 4 1 1 1 1
Less than 2.5mm 11 5 3 1
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Fig 5. Effect of basilica vein size on the primary patency of
brachiobasilic arteriovenous fistulas. The dashed bar illustrates the
point at which the Kaplan-Meier curve becomes unreliable.rach
)BAV
)follow-up time.
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the early postoperative course to identify failing AVFs,
which may have been salvageable by secondary proce-
dures.26 Recent randomized studies, published after the
inclusion dates of this study have also suggested that sur-
veillance may improve the patency of both access grafts and
autogenous fistulas.27,28 We have modified our practice
and now institute a 2-week review with a vascular access
nurse specialist followed by duplex surveillance. As such, we
anticipate that with increased familiarity with the technique
and a rigorous postoperative assessment before and during
dialysis, failures can be reduced and results significantly
improved.
This is a retrospective series, within which selection for
either procedure was influenced by surgeon preference,
anatomic suitability, and the urgency for access for dialysis
due to late referral or access failure. Relative to many
centers within the United Kingdom, we have a high pros-
thetic graft use (5% of primary access in this cohort and 14%
of prevalent dialysis population), thus reflecting a prefer-
ence for definitive surgically created access to long-term
dialysis catheters.29 In such a retrospective series, it is
difficult to objectively measure urgency and thus assess the
effect that may have on choosing a particular access proce-
dure. Furthermore, not all patients are anatomically suit-
able for BBAVF; however, within this series, approximately
40% of patients were deemed appropriate to attempt the
procedure. Most studies to date have defined that the
basilic vein should be at least 3 mm8,30,31 or 4 mm15 in
diameter before proceeding to BBAVF; however, the evi-
dence for this rationale is limited.1,32 In the subgroup of
patients who had a preoperative duplex scan in this study,
we found that even preoperative vein diameters of less than
2.5 mm produced proportions of functional BBAVF equiv-
Table V. Literature review of results of BBAVF
Author
Year of
publication
Number of
BBAVF
Hatjibaloglou39 1992 22
Rivers40 1993 65
Coburn9 1994 59
Hakaim6 1998 26
Matsuura13 1998 30
El Mallah41 1998 40
Humphries42 1999 67
Murphy43 2000 74
Oliver14 2001 59
Ascher30 2001 63
Tsai5 2002 54
Taghizadeh44 2003 75
Segal23 2003 99
Hossny4 2003 70
Lee15 2004 20
Rao7 2004 56
Hill10 2005 32
Keuter22 2005 31
Wolford8 2005 100
BBAVF, Brachiobasilic arteriovenous fistula.alent to those in patients with larger veins.Another important finding within our study is the effect
of surgeons in training on outcomes in tertiary access.
Although it has been suggested that the surgeon has a
major effect on the outcome of AVF formation,33 we have
previously shown that trainee surgeons can attain outcomes
as good as their trainers in primary access surgery.24 In this
study we found that in both the BBAVF group and access
graft groups, surgeons in training did not have a statistically
worse outcome than consultants. However, we acknowl-
edge that selection of appropriate cases for the trainee is
required to obtain such results. We have no explicit guide-
lines to define cases suitable for a trainee in our center, but
we do not doubt that selection bias may undermine our
findings. We strongly believe than vascular access surgeons
should be encouraged to involve surgeons in training in this
expanding specialty.
Similar to the four other studies9,13-15 comparing the
two access procedures, we found significant differences in
infective complications, with no BBAVF lost to infection,
compared with 6% of access grafts. Avoiding such serious
complications and associated patient morbidity provides a
forceful argument in favor of autogenous access. However,
we found no differences in the rates of intervention for steal
syndrome or cardiac failure in our series, and the reported
prevalence of these complications was low.14
We found that patients who had a BBAVF had an
improved survival compared with those who had under-
gone insertion of an access graft. One explanation is that we
may be inserting access grafts into patients whomwe do not
expect to have lengthy survival. However, this finding is in
keeping with previously published data suggesting that
patients with autogenous fistulas have a lower mortality
than those with prosthetic grafts.34,35 The possible reasons
for this are complex but undoubtedly include morbidity
lure to mature
chnical failure
1 year primary
patency
1 year secondary
patency
81%
58%
90%
0% 79%
0% 85%
10%-40% 50-80%
84%
32% 73%
21% 64%
9% 69%
0% 89% 95.9%
8% 66%
23% 47%
5.7% 84.2%-90%
80%
38% 35% 47%
3% 58% 90%
21% 23% 47%Fai
or teassociated with access-related complications and differ-
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urgency for need for dialysis access. Patients urgently re-
quiring access for dialysis due to acute or late referral or due
to access failure are generally more unwell. To avoid
lengthy use of central venous dialysis catheters, these pa-
tients in our unit often have an access graft inserted to allow
a short lead-in time to dialysis via a surgically created access.
However, in this study we found no statistical difference in
age, in the proportion of patients in each group who were
referred late, or who failed to establish dialysis on a radio-
cephalic or brachiocephalic fistula before having tertiary
access.
Like the four previous studies, the results of an isolated
single-center retrospective series may not be viewed as
representative. The lack of randomized controlled trials in
vascular access surgery is often noted.36 However, some
clinicians may be of the opinion that that a randomized
study comparing BBAVF and brachioaxillary access grafts is
unnecessary given the available nonrandomized controlled
trial data relating to infective complications.
We hypothesized we may find greater differences be-
tween BBAVF and access grafts than previous series be-
cause of the high use of autogenous access in our center.
The fact that we have found that in terms of 1-year primary
and secondary patency, access grafts appear slightly better,
although not statistically significantly so, is worthy of fur-
ther discussion. The unit policy has always been to base
access placement on clinical assessment, with little use of
duplex scanning. In this series, of those who went on to
need tertiary access, approximately a quarter had been
established on dialysis by using a wrist or brachiocephalic
fistula (Table II). Indeed, with placing radiocephalic and
brachiocephalic AVFs, a policy of selective duplex scanning
is supported by the literature.37 However, for patients
requiring tertiary access, we have persevered with selective
use of duplex scanning, on the basis of surgical preference at
the time of assessment. As such, our BBAVF outcomes may
be worse than expected because of differences in case
selection and worse than many of those series from North
America, where autogenous access placement is tradition-
ally low,17 and rely heavily on preoperative imaging.38 As
previously discussed, we have subsequently changed our
unit policy and await the effect on our outcomes.
CONCLUSION
We have shown that BBAVFs provide patency statisti-
cally equivalent to brachioaxillary access grafts. However,
infective complications are less and patient survival seems
greater in the BBAVF group. As such, we believe that
BBAVFs should be the first choice of the vascular access
surgeon when fistulas using the cephalic vein are not pos-
sible or have failed.
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